Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 212, Issue 11, Pages 1869-1882Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20151403
Keywords
-
Categories
Funding
- National Institutes of Health [1U01AI095542, R01DE021255, R21CA16719, 1RO1CA176695]
Ask authors/readers for more resources
Group 3 ILCs (ILC3s) are innate sources of IL-22 and IL-17 and include lymphoid tissue-inducer (LTi)-like and NKp46(+) subsets. Both depend on ROR gamma t and aryl hydrocarbon receptor, but NKp46(+) ILC3s also require Notch and T-bet for their development and are transcriptionally distinct. The extent to which these subsets have unique functions, especially in the context of T cell-and B cell-sufficient mice, remains largely unclear. To investigate the specific function of NKp46(+) ILC3s among other ILC3 subsets and T cells, we generated mice selectively lacking NKp46(+) ILC3s or all ILC3s and crossed them to T cell-deficient mice, thus maintaining B cells in all mice. In mice lacking T cells, NKp46(+) ILC3s were sufficient to promote inflammatory monocyte accumulation in the anti-CD40 innate colitis model through marked production of GM-CSF. In T cell-competent mice, lack of NKp46(+) ILCs had no impact on control of intestinal C. rodentium infection, whereas lack of all ILC3s partially impaired bacterial control. Thus, NKp46(+) ILC3s have a unique capacity to promote inflammation through GM-CSF-induced accumulation of inflammatory monocytes, but are superseded by LTi-like ILC3s and T cells in controlling intestinal bacterial infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available